Mechanism of actinomycin D-induced resistance in Ridgway osteogenic sarcoma: an ultrastructural study

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Ridgway osteogenic sarcoma (ROS) is a model for studying cancer drug resistance.
• Actinomycin D (act-D) is an important chemotherapeutic agent.
• Understanding drug resistance mechanisms is crucial for improving cancer treatment.

Purpose of the Study:

• To investigate the ultrastructural changes in actinomycin D sensitive and resistant ROS sublines.
• To correlate these changes with the proposed mechanisms of drug resistance.

Main Methods:

• Development of an actinomycin D resistant ROS subline (ROS/ADX/G2) through repeated suboptimal treatment.
• Single intraperitoneal injection of actinomycin D (0.3 microgram/g) in tumor-bearing animals.
• Ultrastructural examination of tumor cells at 1, 6, and 24 hours post-injection.

Main Results:

• Actinomycin D treatment induced nucleolar segregation in both sensitive and resistant ROS cells.
• The time-scale of nucleolar segregation differed between the sublines.
• Resistant cells (ROS/ADX/G2) showed a more rapid return to normal nucleolar structure.

Conclusions:

• The accelerated recovery from nucleolar segregation in resistant cells supports mechanisms of reduced drug retention.
• Increased drug detoxification may also contribute to acquired actinomycin D resistance in ROS.
• These findings provide insights into the cellular basis of chemoresistance.